In the beginning of this year Prana was in Nasdaq 1.52 and yesterday it ended to 3.13 level. So it is up over 100% in 3 months. It seems evident that Prana will start testing " acute indications " with PBT2 and movement disorders with PBT434.
There are some 5 M Parkinson's disease patients in the world ( under 1M in the USA), some 100 M Essential tremor patients. If PBT2 will be tested in postoperative delirium, there would be perhaps 100 M potential patients to use it for few weeks, if it would prevent delirium. So the potential is huge for both PBT2 and PBT434.
Everything depends on the clinical study results. The results need to demonstrate clinical efficacy. There are many other indications to be tested.
The gap between the present value and the possible value in the future is huge. The disappointment 3 years ago is still depressing the value. There is not enough trust that the studies are planned well enough because last time they were not. Imagine study had too few patients and the primary goal was totally wrong because there was not enough understanding of AD in the world. Reach2HD was too short and imaging side had not enough cases.
2 safe drugs with very many possible indications in which there are no other drugs at present is worth of much more Prana is today (IMO) but only more positive results in well planned clinical studies can change the value. Only then we could speak about market cap as billions.
(20min delay)